MedRhythms, in collaboration with Boston University, is launching a clinical trial of its pipeline asset MR-005 in Parkinson’s disease (PD).
In addition, the company is expanding its pipeline into aging with the development of its Aging Scientific Advisory Board (SAB). This follows MedRhythms’ announcement of the advancement of its pipeline into PD and multiple sclerosis (MS) in 2020 with the initiation of clinical trials and the development of MS and PD SABs.
MedRhythms, headquartered in Portland, Me, is a digital therapeutics company that builds direct stimulation solutions that use clinical-grade sensors, software and music to help restore function lost to neurologic disease or injury.